Background There is increasing recognition of myocardial angiotensin-converting enzyme, which is induced with the development of left ventricular hypertrophy (LVH). The potential physiological significance of subsequent increased angiotensin I to II conversion in the presence of LVH is unclear
) and low-dose (1.5 mg, n= 10) IC enalaprilat during a 30-minute infusion at 1 mL/min. The high-dose patients were further divided along the median normalized LV wall thickness of 0.671 cm/M2. The time constant of isovolumic relaxation (TauL) was prolonged at baseline in patients receiving high-dose enalaprilat with wall thickness >0.671 cm/m2 (TauL, 56±2 versus 44±2 and 45±2 milliseconds, respectively, P<.01 by ANOVA) and shortened only in this patient group (TauL, 49±3 versus 46±2 and 43±2 milliseconds, respectively, P<.01 versus baseline and other groups by ANOVA). The improvement in TauL was directly proportional to the degree of LVH (r=.92, P<.001). Although there was a decrease in LV end-diastolic pressure (23±2 to 15±1 mm Hg, P<.01) and volume (86±8 to 67±9 mL/m2, P<.05) in those patients with a reduction in TauL, this is due to movement down a similar diastolic pressure-volume relation with no change in chamber elastic stiffness (0.023±0.002 to 0.025±0.004 mL-1, P=NS).
Conclusions Intracoronary enalaprilat resulted in an improvement in active (Ca2-dependent) relaxation in those patients with more severe hypertensive LVH. The improvement in active relaxation was directly proportional to the severity of LVH. These results support the hypothesis that the cardiac renin-angiotensin system is an important determinant of active diastolic function in hypertensive LVH. (Circulation. 1994;89:2616-2625.)
Key Words * hypertrophy * diastole * angiotensin . enzymes * enalaprilat Angiotensin-converting enzyme inhibitors have gained widespread use in the therapy of chronic hypertension and secondary left ventricular hypertrophy (LVH). This is due in part to the recognition of the role of the circulating renin-angiotensin system in the pathophysiology of essential hypertension and LVH.1 More recently, the existence of a physiologically active cardiac renin-angiotensin system has been demonstrated, with evidence of local synthesis of angiotensinogen, renin, angiotensin-converting enzyme, and angiotensin-converting enzyme mRNA in the heart.2-9 Nevertheless, the local physiological effects of angiotensin II on cardiac function remain to be clarified.
The effects of the cardiac renin-angiotensin system on ventricular function may be important in the pathophysiology and hemodynamic consequences of LVH Table 2 . At baseline, load and heart rate were similar in all three groups of patients. LV preload (LV end-diastolic volume index) fell only in patients given high-dose IC enalaprilat. Among those patients who received the high dose, the greatest preload reduction was observed in those with The diastolic hemodynamic parameters of the patients given the 1.5-mg dose (n= 10) and the patients given the 5.0-mg dose (n= 15) of IC enalaprilat are shown in Table  3 . At baseline, TauL was significantly prolonged in patients with severe LVH given high-dose enalaprilat (P=.003 by ANOVA). Furthermore, patients with severe LVH tended to have greater abnormalities in passive LV diastolic function, as measured by LV chamber stiffness (P=.058 by ANOVA). After IC enalaprilat, PCWP and LV end-diastolic pressure were reduced in patients with severe LVH given the 5.0-mg dose.
Active relaxation was improved with the 5.0-mg dose of IC enalaprilat in those with severe LVH, as indicated by improvements in the time constants of isovolumic relaxation (TauL and TauG) and minimum LVP (LVPmin). Conversely, the early transmitral gradient (PCWP-LVP,,i,,n) and the peak filling rate (dV/ dtmax) were unchanged with IC enalaprilat despite an improvement in active relaxation in patients with severe LVH. Passive LV diastolic function (chamber elastic stiffness) was also unaffected by IC enalaprilat administration. The magnitude of the improvement in active relaxation with IC enalaprilat (reduction in TauL) was directly proportional to the degree of LVH in these patients (Fig 2, r=. The systolic hemodynamic parameters of the patients given the 1.5-mg dose (n= 10) and the patients given the 5.0-mg dose (n=15) of IC enalaprilat are shown in Table 4 . At baseline, the three groups of patients were similar with respect to all systolic hemodynamic parameters. Among patients who received the 5.0-mg dose of IC enalaprilat, LV systolic pressure, SWI, and preload recruitable stroke work fell in the patients without severe LVH, whereas cardiac index and end-systolic elastance fell in the patients with severe LVH. Nevertheless, the effects of IC enalaprilat administration on all systolic hemodynamic parameters were similar in the three groups by ANOVA.
Discussion
The present study demonstrates the beneficial acute hemodynamic effects of local cardiac angiotensin-converting enzyme inhibition in patients with hypertensive LVH. Intracoronary enalaprilat administration resulted in an improvement in active (Ca'+-dependent) relaxation in those with more severe LVH. Furthermore, this improvement in active relaxation was directly proportional to the severity of LVH in these patients. The greater the LVH, the greater the improvement in active (Ca'+-dependent) relaxation. The reduction in PCWP in high-dose patients with severe LVH provided an additional hemodynamic benefit. This benefit, however, was not due to improvements in early diastolic filling or LV compliance, since the peak LV filling rate (dV/ dtmax) and chamber stiffness were unaffected by acute IC angiotensin-converting enzyme inhibition. LV filling pressures were reduced because of movement down a similar LV diastolic pressure-volume relation secondary to a reduction in preload rather than any intrinsic change in passive LV diastolic function.
The results of the present study support the hypothesis that the cardiac renin-angiotensin system is an important determinant of active diastolic function in hypertensive LVH. Angiotensin II administration has been shown to increase the L-type Ca'+ current independently of adenylate cyclase, with a subsequent decrease in relaxation velocity,28 and affects the mobilization and reuptake of cytosolic free with the premise that inhibition of cardiac angiotensin II production would result in improvement in active (Ca2-dependent) relaxation. Furthermore, the fact that the degree of improvement in Tau with IC angiotensin-converting enzyme inhibition is directly proportional to the severity of LVH provides physiological evidence that the cardiac renin-angiotensin system is induced to a greater extent with increasing LVH.2,7-915 These findings are even more impressive because the mode of administration of enalaprilat via only the left coronary artery might be expected to cause regional asynchrony, which should retard active relaxation rather than improve it.
The reduction in preload after high-dose IC enalaprilat administration merits further comment. There were significant reductions in LV end-diastolic volume indexes seen in patients with and without severe LVH who received high-dose IC enalaprilat. It is unlikely that this observed preload reduction could have been due to volume depletion secondary to the nonionic contrast used during the diagnostic cardiac catheterization, because patients given the low dose of IC enalaprilat did not demonstrate any significant hemodynamic effects despite a similar experimental protocol (see Fig 3) . This probably reflects a systemic concentration of enalaprilat despite its IC route of administration, with inhibition of bradykinin degradation in the venous system.29 Bradykinin has been shown to produce venodilation both because of direct effects30,31 and secondary to its effects on prostaglandins30,32 and endothelium-derived relaxing factor.30,33 This preload reduction may be responsible for the absence of improvement in the rate of early LV filling. An improvement in active diastolic function might be expected to improve the rate of early LV filling by increasing the early transmitral gradient.3435 Although IC enalaprilat administration improved active diastolic function (Tau) in patients with LVH, the expected secondary improvement in peak early LV filling (dV/dtmax) did not occur. This may have been due to the accompanying preload reduction. Nevertheless, the reductions in LV filling pressures with angiotensinconverting enzyme inhibition provide additional hemodynamic benefit in patients with hypertensive LVH.
The present study demonstrated that although IC angiotensin-converting enzyme inhibition improved active relaxation, it did not affect the passive late diastolic properties of the LV as assessed either by a calculated LV chamber stiffness or the visual appearance of the LV diastolic pressure-volume relation. These results are contrary to those of others,78 who concluded in an isolated perfused rat heart model that alterations of the cardiac renin-angiotensin system acutely changed diastolic compliance in hypertrophied hearts compared with controls. They further postulated that these effects on passive diastolic function must be secondary to changes in active Ca2' handling mediated by the cardiac renin-angiotensin system. However, these changes were observed in an isovolumic preparation. 
